literature

HIV mutation literature information.

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.

PMID: 23361642 2013 The Journal of antimicrobial chemotherapy

Abstract: We studied the primary rilpivirine RAMs (K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, H221Y, F227C and M230I/L) and other potential rilpivirine-associated mutations (V90I, L100I, K101T, E138S, V179D/I, Y188L, V189I, G190A/E/S and M230V).

HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.

PMID: 23372113 2013 HIV clinical trials

Abstract: Among 87 participating individuals with VL >=1,000 copies/mL, 11 people still harbored a wild-type strain, while 76 participants harbored a HIV-1 drug-resistant strain (2 of which were against protease inhibitors); common DRMs were M184I/V (74%), Y181I/C/V (39%), G190A/S (32%), T215Y/F (32%), and K103N (31%).

Differential impact of resistance-associated mutations to protease inhibitors and nonnucleoside reverse transcriptase inhibitors on HIV-1 replication capacity.

PMID: 23594266 2013 AIDS research and human retroviruses

Abstract: Regarding the effects of resistance to antiretroviral drugs in salvage therapy, decreased replication capacity was noted with the increasing RAMs to darunavir/ritonavir (p<0.001) and specific RAMs (L100I, K101P, and Y181C/I/V) to etravirine (p<0.001).

Replication fitness of multiple nonnucleoside reverse transcriptase-resistant HIV-1 variants in the presence of etravirine measured by 454 deep sequencing.

PMID: 23720723 2013 Journal of virology

Abstract: Using this method, we show that the Y181V mutation in the HIV-1 reverse transcriptase in particular confers a clear selective advantage to the virus over 14 other NNRTI resistance mutations in the presence of etravirine in vitro.

Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.

PMID: 23840622 2013 PloS one

Result: Additional NNRTI-resistance mutations not shown in Table 4 included (i) A98G, which occurred in 3.3% of NNRTI-treated patients; (ii) V106A, which occurred in 0.6% of NNRTI-treated patients; (iii) E138G/Q, which occurred in 0.9% and 0.9% of patients, respectively; (iv) V179D/E/T/F, which occurred in 8.5%, 0.7%, 0.5%, and 0% of NNRTI-treated patients respectively; (v) Y181I/V, which occurred in one and no patient, respectively; (vi) H221Y, which occurred in 5.9% of EFV-treated and 9.3% of NVP-treated patients (p<0.001); (vii) P225H, which occurred in 13.6% of EFV-treate

Persistence of HIV-1 transmitted drug resistance mutations.

PMID: 23904291 2013 The Journal of infectious diseases

Table: Y181 V

Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province, China.

PMID: 24009694 2013 PloS one

Table: Y181V

Increased risk of Q151M and K65R mutations in patients failing stavudine-containing first-line antiretroviral therapy in Cambodia.

PMID: 24015311 2013 PloS one

Result: The most frequently detected mutations were: M184I/V (92.3%), Y181C/I/V (47.1%), T215I/C/F/N/S (38.8%), D67E/G/N (37.3%), K103N/R/S (33.9%), and G190A/Q/S (32.5%).

[Resistance profile of rilpivirine].

PMID: 24252532 2013 Enfermedades infecciosas y microbiologia clinica

Abstract: In vitro studies and phase III clinical trials have allowed the identification of 16 mutations associated with resistance to RPV K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, Y188L, H221Y, F227C and M230I/L.

Prevalence of TMC278 (rilpivirine) associated mutations in the Frankfurt Resistance Database.

PMID: 22209291 2012 Journal of clinical virology

Abstract: OBJECTIVE: Objective of our investigation was to determine the prevalence of mutations E138K, Y181I/V, and K101E/P before the approval of rilpivirine.

Abstract: RESULTS: The E138K, Y181I/V, and the K101E mutations were found in 0.4%, 0.9%, and 2.4% of the patients, respectively.

Browser Board

Co-occurred Entities

Filtrator